Recent progress and considerations for AAV gene therapies targeting the central nervous system

Erik Allen Lykken, Charles Shyng, Reginald James Edwards, Alejandra Rozenberg, Steven James Gray

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Background: Neurodevelopmental disorders, as a class of diseases, have been particularly difficult to treat even when the underlying cause(s), such as genetic alterations, are understood. What treatments do exist are generally not curative and instead seek to improve quality of life for affected individuals. The advent of gene therapy via gene replacement offers the potential for transformative therapies to slow or even stop disease progression for current patients and perhaps minimize or prevent the appearance of symptoms in future patients. Main body: This review focuses on adeno-associated virus (AAV) gene therapies for diseases of the central nervous system. An overview of advances in AAV vector design for therapy is provided, along with a description of current strategies to develop AAV vectors with tailored tropism. Next, progress towards treatment of neurodegenerative diseases is presented at both the pre-clinical and clinical stages, focusing on a few select diseases to highlight broad categories of therapeutic parameters. Special considerations for more challenging cases are then discussed in addition to the immunological aspects of gene therapy. Conclusion: With the promising clinical trial results that have been observed for the latest AAV gene therapies and continued pre-clinical successes, the question is no longer whether a therapy can be developed for certain neurodevelopmental disorders, but rather, how quickly.

Original languageEnglish (US)
Article number16
JournalJournal of Neurodevelopmental Disorders
Volume10
Issue number1
DOIs
StatePublished - May 18 2018

Fingerprint

Dependovirus
Gene Targeting
Genetic Therapy
Central Nervous System
Therapeutics
Tropism
Central Nervous System Diseases
Neurodegenerative Diseases
Disease Progression
Quality of Life
Clinical Trials
Genes

Keywords

  • AAV9
  • Adeno-associated virus
  • Cellular immunity
  • Central nervous system
  • Clinical trial
  • Gene therapy
  • Neutralizing antibody

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Recent progress and considerations for AAV gene therapies targeting the central nervous system. / Lykken, Erik Allen; Shyng, Charles; Edwards, Reginald James; Rozenberg, Alejandra; Gray, Steven James.

In: Journal of Neurodevelopmental Disorders, Vol. 10, No. 1, 16, 18.05.2018.

Research output: Contribution to journalReview article

Lykken, Erik Allen ; Shyng, Charles ; Edwards, Reginald James ; Rozenberg, Alejandra ; Gray, Steven James. / Recent progress and considerations for AAV gene therapies targeting the central nervous system. In: Journal of Neurodevelopmental Disorders. 2018 ; Vol. 10, No. 1.
@article{a1eceaee91644c70b1371e96ea04aca4,
title = "Recent progress and considerations for AAV gene therapies targeting the central nervous system",
abstract = "Background: Neurodevelopmental disorders, as a class of diseases, have been particularly difficult to treat even when the underlying cause(s), such as genetic alterations, are understood. What treatments do exist are generally not curative and instead seek to improve quality of life for affected individuals. The advent of gene therapy via gene replacement offers the potential for transformative therapies to slow or even stop disease progression for current patients and perhaps minimize or prevent the appearance of symptoms in future patients. Main body: This review focuses on adeno-associated virus (AAV) gene therapies for diseases of the central nervous system. An overview of advances in AAV vector design for therapy is provided, along with a description of current strategies to develop AAV vectors with tailored tropism. Next, progress towards treatment of neurodegenerative diseases is presented at both the pre-clinical and clinical stages, focusing on a few select diseases to highlight broad categories of therapeutic parameters. Special considerations for more challenging cases are then discussed in addition to the immunological aspects of gene therapy. Conclusion: With the promising clinical trial results that have been observed for the latest AAV gene therapies and continued pre-clinical successes, the question is no longer whether a therapy can be developed for certain neurodevelopmental disorders, but rather, how quickly.",
keywords = "AAV9, Adeno-associated virus, Cellular immunity, Central nervous system, Clinical trial, Gene therapy, Neutralizing antibody",
author = "Lykken, {Erik Allen} and Charles Shyng and Edwards, {Reginald James} and Alejandra Rozenberg and Gray, {Steven James}",
year = "2018",
month = "5",
day = "18",
doi = "10.1186/s11689-018-9234-0",
language = "English (US)",
volume = "10",
journal = "Journal of Neurodevelopmental Disorders",
issn = "1866-1947",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Recent progress and considerations for AAV gene therapies targeting the central nervous system

AU - Lykken, Erik Allen

AU - Shyng, Charles

AU - Edwards, Reginald James

AU - Rozenberg, Alejandra

AU - Gray, Steven James

PY - 2018/5/18

Y1 - 2018/5/18

N2 - Background: Neurodevelopmental disorders, as a class of diseases, have been particularly difficult to treat even when the underlying cause(s), such as genetic alterations, are understood. What treatments do exist are generally not curative and instead seek to improve quality of life for affected individuals. The advent of gene therapy via gene replacement offers the potential for transformative therapies to slow or even stop disease progression for current patients and perhaps minimize or prevent the appearance of symptoms in future patients. Main body: This review focuses on adeno-associated virus (AAV) gene therapies for diseases of the central nervous system. An overview of advances in AAV vector design for therapy is provided, along with a description of current strategies to develop AAV vectors with tailored tropism. Next, progress towards treatment of neurodegenerative diseases is presented at both the pre-clinical and clinical stages, focusing on a few select diseases to highlight broad categories of therapeutic parameters. Special considerations for more challenging cases are then discussed in addition to the immunological aspects of gene therapy. Conclusion: With the promising clinical trial results that have been observed for the latest AAV gene therapies and continued pre-clinical successes, the question is no longer whether a therapy can be developed for certain neurodevelopmental disorders, but rather, how quickly.

AB - Background: Neurodevelopmental disorders, as a class of diseases, have been particularly difficult to treat even when the underlying cause(s), such as genetic alterations, are understood. What treatments do exist are generally not curative and instead seek to improve quality of life for affected individuals. The advent of gene therapy via gene replacement offers the potential for transformative therapies to slow or even stop disease progression for current patients and perhaps minimize or prevent the appearance of symptoms in future patients. Main body: This review focuses on adeno-associated virus (AAV) gene therapies for diseases of the central nervous system. An overview of advances in AAV vector design for therapy is provided, along with a description of current strategies to develop AAV vectors with tailored tropism. Next, progress towards treatment of neurodegenerative diseases is presented at both the pre-clinical and clinical stages, focusing on a few select diseases to highlight broad categories of therapeutic parameters. Special considerations for more challenging cases are then discussed in addition to the immunological aspects of gene therapy. Conclusion: With the promising clinical trial results that have been observed for the latest AAV gene therapies and continued pre-clinical successes, the question is no longer whether a therapy can be developed for certain neurodevelopmental disorders, but rather, how quickly.

KW - AAV9

KW - Adeno-associated virus

KW - Cellular immunity

KW - Central nervous system

KW - Clinical trial

KW - Gene therapy

KW - Neutralizing antibody

UR - http://www.scopus.com/inward/record.url?scp=85047563233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047563233&partnerID=8YFLogxK

U2 - 10.1186/s11689-018-9234-0

DO - 10.1186/s11689-018-9234-0

M3 - Review article

VL - 10

JO - Journal of Neurodevelopmental Disorders

JF - Journal of Neurodevelopmental Disorders

SN - 1866-1947

IS - 1

M1 - 16

ER -